Link to Article Learn more about the development of CyberCell™, a virtual reality education program designed to help adolescents and young adults with sickle cell disease better understand…
Patrick Neven, MD, Universitair Ziekenhuis Leuven, Leuven, Belgium, presents data from the EMBER-2 window-of-opportunity study, in which imlunestrant was given for about 2 weeks before surgery in women…
In this panel discussion from the 7th International Workshop on Acute Leukemias, Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY; Andrew Wei, MBBS, PhD, Peter MacCallum…
Lung cancer comes in two main types: non-small cell and small cell. Each has different patterns, growth rates, and treatment needs. Smoking is the top risk factor, but…
Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, reviews the role of FLT3 inhibitors for treating patients with FLT3-mutated acute myeloid leukemia. Dr Perl discusses how FLT3 inhibitors…
Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the challenges and advancements in treating acute myeloid leukemia (AML) in patients who are unfit for intensive…
Teri Foy, PhD, Senior Vice President, Cancer Immunology and Cell Therapy Thematic Research Center and Seattle site lead, and Mike Burgess, MD, PhD, Senior Vice President, Head of…
In an interview that took place at the European Society for Medical Oncology 2024 Congress in Barcelona, Spain, Timothy Yap, MBBS, PhD, medical oncologist, The University of Texas…
